Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (401-410 of 768) with videos related to

Pageof 77
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomesKoen van Besien, Jeanette Carreras, Philip J Bierman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantationJonas A de Souza, Rima M Saliba, Poliana Patah, et al.
International Journal of Hematology|December 10, 2009
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancerYee Chung Cheng, Gabriela Rondón, Leah F Sanchez, et al.
Bone Marrow Transplantation|December 12, 2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDSGheath Alatrash, Kelly M Kidwell, Peter F Thall, et al.
Leukemia Research Reports|July 4, 2025
Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasmQaiser Bashir, Marina Konopleva, Glorette Abueg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphomaC Hosing, M Munsell, S Yazji, et al.
Leukemia & Lymphoma|October 26, 2011
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantQaiser Bashir, Mark F Munsell, Sergio Giralt, et al.
Leukemia & Lymphoma|January 17, 2012
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplantAmer M Beitinjaneh, Rima Saliba, Qaiser Bashir, et al.
Bone Marrow Transplantation|June 27, 2006
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemiaP Kebriaei, R M Saliba, C Ma, et al.
Pageof 77

Showing results (401-410 of 768) with videos related to

Sort By:
Pageof 77
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomesKoen van Besien, Jeanette Carreras, Philip J Bierman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantationJonas A de Souza, Rima M Saliba, Poliana Patah, et al.
International Journal of Hematology|December 10, 2009
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancerYee Chung Cheng, Gabriela Rondón, Leah F Sanchez, et al.
Bone Marrow Transplantation|December 12, 2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDSGheath Alatrash, Kelly M Kidwell, Peter F Thall, et al.
Leukemia Research Reports|July 4, 2025
Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasmQaiser Bashir, Marina Konopleva, Glorette Abueg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphomaC Hosing, M Munsell, S Yazji, et al.
Leukemia & Lymphoma|October 26, 2011
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantQaiser Bashir, Mark F Munsell, Sergio Giralt, et al.
Leukemia & Lymphoma|January 17, 2012
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplantAmer M Beitinjaneh, Rima Saliba, Qaiser Bashir, et al.
Bone Marrow Transplantation|June 27, 2006
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemiaP Kebriaei, R M Saliba, C Ma, et al.
Pageof 77